Posts Tagged ‘PhRMA’

MEDIA ADVISORY – Partnership to Fight Chronic Disease Presents: Chronic Disease: A Common Sense Approach to Solving Complex Health Issues

Posted: Nov 9, 2012 | Posted by Kassy Perry | No Comments

The Partnership to Fight Chronic Disease (PFCD) is an international coalition of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs in the world: chronic disease

WHAT:
PFCD is hosting a forum focusing on the challenges chronic, non communicable disease presents to California and the United States. During this event we will seek better understand the impact of these issue and what role technology can play in improving patient outcomes and reducing rising health care costs.

WHEN:
Tuesday, November 27, 2012 – 10:00 a.m. – 1:00 p.m.

WHERE:
Hotel Sainte Claire, 302 South Market Street, San Jose, CA 95113

WHO:
Kenneth Thorpe, PhD, Chairman, Partnership to Fight Chronic Disease, Professor and Chair,
Robert W. Woodruff Professor, Rollins School of Public Health , Emory University
Thomas Goetz, Executive Editor, Wired Magazine
Dr. Travis Stork, Healthy Lifestyle Author; Emergency Room Physician and Host, “The Doctors”
Susan Dentzer, Editor-in-Chief, Health Affairs
Dr. Kent Bradley, Senior Vice President and Chief Medical Officer, Safeway
Steve Skurnac, President, Sims Recycling Solutions
Dr. Julie Andersen, Professor and Researcher, Buck Institute for Age Research
Dr. John Farquhar, MD, Professor of Medicine and Health Research and Policy, Founder and Senior Faculty Member, Stanford Prevention Research Center
Sandra Perez, Director, California Office of the Patient Advocate
Micah Weinberg, Senior Policy Advisor, Bay Area Council

This forum is sponsored by Bay Area Council, The Buck Institute for Research on Aging, California Chronic Care Coalition, California Partnership for Access to Treatment, H.E.A.R.T., KGO Radio, PhRMA, San Jose Silicon Valley Chamber of Commerce, San Jose Mercury News and Silicon Valley/ San Jose Business Journal.

California Companies Target Heart Disease, Cancer With More Than 240 Medicines in Development

Posted: May 23, 2011 | Posted by Kassy Perry | No Comments

WASHINGTON–(BUSINESS WIRE)–At a time when cancer and heart disease are the nation’s and the world’s top killers, biopharmaceutical research companies headquartered in California are developing 243 of the 1,186 medicines in development for those dreaded diseases.

The California companies are developing 188 of 887 drugs for more than 20 types of cancer and 55 of 299 medicines for heart disease and stroke.

The cancer statistics are contained in a new report “Medicines in Development for Cancer” published by the Pharmaceutical Research and Manufacturers of America (PhRMA), while the data on heart disease and stroke are from a PhRMA report from early this year.

The cancer report and “Medicines in Development for Heart Disease and Stroke” can be found on the PhRMA website, www.phrma.org.
READ MORE

Kassy Perry with a three-peat appearance on Capitol Weekly’s Political Warriors List!

Posted: Apr 22, 2011 | Posted by Kassy Perry | No Comments

Capitol Weekly looks at 100 political warriors

92. Kassy Perry
Kassy Perry’s communications firm – she’s not a lobbyist – specializes in health issues, and her role is likely to expand as some version of health care reform takes root in California. She represents myriad companies and groups such as Aetna U.S. Healthcare, PhRMA, MAXIMUS, Johnson & Johnson, Pfizer and Merck, who are deeply interested in California’s health reform issues. In 2008, in something of a departure for Perry, she was called in to try and salvage the sputtering No on Prop. 8 campaign.

View the full article on Captiol Weekly

PhRMA Report: Biopharmaceutical Companies in California Lead the Fight Against Heart Disease, Stroke

Posted: Mar 24, 2011 | Posted by Kassy Perry | No Comments

Washington, D.C. (March 23, 2011) —California’s biopharmaceutical companies are working on nearly one-fifth of new medicines being developed for heart disease and stroke, according to a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA).    

The report shows California companies are developing 55 of 299 new medications for cardiovascular disease.   

“Since 1900, heart disease has topped the list of killer diseases every year but one – 1918 – and stroke is the fourth leading cause of death in America,” PhRMA Deputy Vice President Karl Uhlendorf said today.  “In California, according to the state’s Heart Disease and Stroke Prevention Program, heart disease and stroke are the number one and three causes of death, and a leading cause of disability.  Californians can take heart in knowing that new hope is on the horizon and much of it stems from the innovation of biopharmaceutical companies located throughout the state.”   

New medicines offer the potential for not only improved health, but also lower health care costs.  And, in California, there is a strong need for relief from the burdensome expenses of heart disease.  Average health care spending for cardiovascular patients is nearly six times the average for all patients in the state, according to “Chronic Diseases in California:  Facts and Figures,” a recent report by the California Health Care Foundation. 
READ MORE

Case Study: California Partnership for Access to Treatment

Posted: Feb 16, 2011 | Posted by Kassy Perry | No Comments

Communities Bond for Health

Research-based pharmaceutical companies have been on the front lines of health system reform for years, advocating for improved access to care for all Americans. Collaboration with health advocacy organizations was natural, given patients’ need for innovative medicines to preserve quality of life, relieve symptoms, reduce hospitalizations and prevent death. Patients aren’t the only stakeholders, however; and while some groups choose advocacy others need a communications and resource network for the communities they serve.

PCG created and implemented the California Partnership for Access to Treatment to engage diverse stakeholders and launch a multi-faceted dialog about all health care issues. Monthly educational seminars continue to provide an opportunity for previously unrelated groups to convene around common issues, broadening perspectives. Online resources in seven languages offer timely information and additional opportunities for the more than 1400 members to connect. By ensuring a forum that would not become a legislative “action team,” CPAT drew health advocates together with ethnic communities, employers and health care providers, creating a shared bond despite unique perspectives.

READ MORE